teaser
This review considers analyses undertaken on the economic impact of healthcare-acquired infections and the pharmacoeconomic impact of new drug therapies, including antibiotics such as linezolid
Dilip Nathwani
MB FRCP DTM&H
Consultant Physician and Honorary Professor
Infection Unit
Ninewells Hospital and Medical School
Dundee
UK
SENTRY antimicrobial programme data for 1997
